APA (7th ed.) Citation

Kwak, S. H., Han, K. A., Kim, K., Yu, J. M., Kim, E., Won, J. C., . . . Park, K. S. (2023). Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III trial. Diabetes, obesity & metabolism, 25(7), 1865-1873. https://doi.org/10.1111/dom.15046

Chicago Style (17th ed.) Citation

Kwak, Soo Heon, et al. "Efficacy and Safety of Enavogliflozin, a Novel SGLT2 Inhibitor, in Korean People with Type 2 Diabetes: A 24‐week, Multicentre, Randomized, Double‐blind, Placebo‐controlled, Phase III Trial." Diabetes, Obesity & Metabolism 25, no. 7 (2023): 1865-1873. https://doi.org/10.1111/dom.15046.

MLA (9th ed.) Citation

Kwak, Soo Heon, et al. "Efficacy and Safety of Enavogliflozin, a Novel SGLT2 Inhibitor, in Korean People with Type 2 Diabetes: A 24‐week, Multicentre, Randomized, Double‐blind, Placebo‐controlled, Phase III Trial." Diabetes, Obesity & Metabolism, vol. 25, no. 7, 2023, pp. 1865-1873, https://doi.org/10.1111/dom.15046.